Trimbow Aerosol, Metered
NDC Package 10122-121-02
Package Information
Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate) aerosols is tRIMBOW is indicated for the maintenance treatment of asthma in adult patients aged 18 years and older. This formulation utilizes a aerosol, metered delivery system. Marketed by Chiesi Usa, Inc., this product is identified by NDC 10122-121 and is authorized under FDA application NDA219622.
Identification & Billing
Clinical Specifications
- Adrenergic beta2-Agonists - [MoA] (Mechanism of Action)
- Anticholinergic - [EPC] (Established Pharmacologic Class)
- Cholinergic Antagonists - [MoA] (Mechanism of Action)
- Cholinergic Muscarinic Antagonist - [EPC] (Established Pharmacologic Class)
- Cholinergic Muscarinic Antagonists - [MoA] (Mechanism of Action)
- Corticosteroid Hormone Receptor Agonists - [MoA] (Mechanism of Action)
- Corticosteroid - [EPC] (Established Pharmacologic Class)
- beta2-Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 10122 - Chiesi Usa, Inc.
- 10122-121 - Trimbow
- 10122-121-02 - 1 CANISTER in 1 CARTON / 120 AEROSOL, METERED in 1 CANISTER
- 10122-121 - Trimbow
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 10122-121-02 identifies a specific commercial package of 1 canister in 1 carton / 120 aerosol, metered in 1 canister of Trimbow, a human prescription drug labeled by Chiesi Usa, Inc.. This aerosol, metered is formulated for respiratory (inhalation) use and contains beclomethasone dipropionate; formoterol fumarate; glycopyrrolate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Chiesi Usa, Inc. on May 14, 2026. The current certification is valid through December 31, 2027.
How is this Chiesi Usa, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 10122012102. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.